Castle Biosciences Issues Inducement Grants to 172 New Employees

These restricted stock units operate on a four-year vesting schedule. One-quarter of the shares will vest on the first anniversary of each individual's start date, with the remaining balance distributed in three equal annual installments. This structure remains contingent upon the employees maintaining continuous service with the company throughout the entire vesting period.

Castle Biosciences, which trades on the Nasdaq under the ticker CSTL, focuses on developing molecular tests for dermatologic and gastroenterological conditions. The company utilizes these equity grants to attract talent as it continues to expand its portfolio of diagnostic solutions, including its suite of DecisionDx and TissueCypher products.